EcoDrugPlus

Smoothened, Frizzled Class Receptor

Ensembl ID : ENSLBEG00000017169
Gene Symbol: SMO
3 Cross references
204 Possible Orthologues:

Sodium Channel, Voltage Gated, Type V-Like, Alpha B

Ensembl ID : ENSLBEG00000014205
Gene Symbol: SCN5LAB
1 Cross references
262 Possible Orthologues:

Sodium Channel, Voltage Gated, Type Xii, Alpha A

Ensembl ID : ENSLBEG00000003585
Gene Symbol: SCN12AA
1 Cross references
248 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 4

Ensembl ID : ENSLBEG00000026939
Gene Symbol: SCN4A
2 Cross references
191 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSLBEG00000013868
Gene Symbol: SCN8A
2 Cross references
215 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSLBEG00000018924
Gene Symbol: SCN8A
3 Cross references
216 Possible Orthologues:

Sodium- And Chloride-Dependent Gaba Transporter 1-Like

Ensembl ID : ENSLBEG00000007443
Gene Symbol: LOC109980934
3 Cross references
205 Possible Orthologues:

Sodium- And Chloride-Dependent Glycine Transporter 1-Like

Ensembl ID : ENSLBEG00000001270
Gene Symbol: LOC109998534
3 Cross references
208 Possible Orthologues:

Sodium/hydrogen Exchanger 3-Like

Ensembl ID : ENSLBEG00000016376
Gene Symbol: LOC109990226
2 Cross references
232 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Alpha-1

Ensembl ID : ENSLBEG00000014756
Gene Symbol: LOC109990177
2 Cross references
181 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Alpha-1-Like

Ensembl ID : ENSLBEG00000014685
Gene Symbol: LOC109990179
2 Cross references
215 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Alpha-2-Like

Ensembl ID : ENSLBEG00000006058
Gene Symbol: LOC109997514
3 Cross references
205 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).